RHHVF - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD

Roche Holding AG

Konzern-Hauptsitz
Grenzacherstrasse 124
Basel 4070
Switzerland
41 61 688 11 11
http://www.roche.com

Sector
Industry
Full Time Employees94,052

Key Executives

NameTitlePayExercisedAge
Dr. Severin Schwan Ph.D.CEO & Exec. Director7.55MN/A50
Dr. Alan HippeChief Financial & IT Officer3.93MN/A50
Dr. Gottlieb A. KellerGen. Counsel & Corp. Sec.2.99MN/A63
Ms. Cristina A. WilburHead of Group HR1.86MN/A50
Mr. Daniel O'DayChief Exec. Officer of Roche Pharmaceuticals6.87MN/A53
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses worldwide. The company offers pharmaceutical products for anaemia, anticoagulation therapy, bone, cancer, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, drug metabolism disorder, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, human papillomavirus, infectious diseases, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and west nile virus diseases. It also provides diagnostic solutions for blood gas analysis; blood screening; cancer screening; cardiac markers; cardiovascular testing; cholesterol monitoring; coagulation monitoring, routing, and specialty testing; data management; diabetes monitoring and therapy; electrolytes analysis; emergency medicine; hemostasis; heterogeneous immunochemistry; homogenous immune assays; immunology; infectious diseases; intensive care testing; microarray; anti-platelet therapy monitoring; neonatal intensive care; nucleic acid purification; PCR clinical diagnostics and real-time PCR diagnostic systems; pharmacogenomics; physical fitness and platelet function testing; serum work area; urinalysis; and workflow solutions. In addition, the company offers cell analysis, gene expression, genome sequencing, nucleic acid purification, and real-time PCR systems for researchers. Roche Holding AG has a clinical collaboration agreement with Epizyme, Inc. to study tazemetostat administered in combination with atezolizumab for the treatment of patients with relapsed/refractory metastatic non-small cell lung cancer. The company was founded in 1896 and is headquartered in Basel, Switzerland.

Corporate Governance

Roche Holding AG’s ISS Governance QualityScore as of November 1, 2017 is 5. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 1; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.